BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 29427096)

  • 1. Clinical Features of Huntington's Disease.
    Ghosh R; Tabrizi SJ
    Adv Exp Med Biol; 2018; 1049():1-28. PubMed ID: 29427096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntington's Disease: Relationship Between Phenotype and Genotype.
    Sun YM; Zhang YB; Wu ZY
    Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntington's disease: clinical presentation and treatment.
    Novak MJ; Tabrizi SJ
    Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease: a clinical review.
    McColgan P; Tabrizi SJ
    Eur J Neurol; 2018 Jan; 25(1):24-34. PubMed ID: 28817209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Strategies for Huntington's Disease Treatment.
    Colpo GD; Rocha NP; Stimming EF; Teixeira AL
    CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Aspects of Huntington's Disease.
    Ghosh R; Tabrizi SJ
    Curr Top Behav Neurosci; 2015; 22():3-31. PubMed ID: 23975844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and neuropathology of Huntington's disease.
    Reiner A; Dragatsis I; Dietrich P
    Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntington disease.
    Bates GP; Dorsey R; Gusella JF; Hayden MR; Kay C; Leavitt BR; Nance M; Ross CA; Scahill RI; Wetzel R; Wild EJ; Tabrizi SJ
    Nat Rev Dis Primers; 2015 Apr; 1():15005. PubMed ID: 27188817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Study of Triplet-Primed PCR for Identification of CAG Repeat Expansion in the HTT Gene in a Cohort of 503 Indian Cases with Huntington's Disease Symptoms.
    Chheda P; Chanekar M; Salunkhe Y; Dama T; Pais A; Pande S; Bendre R; Shah N
    Mol Diagn Ther; 2018 Jun; 22(3):353-359. PubMed ID: 29619771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington disease.
    Ghosh R; Tabrizi SJ
    Handb Clin Neurol; 2018; 147():255-278. PubMed ID: 29325616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics of Huntington disease.
    Nance MA
    Handb Clin Neurol; 2017; 144():3-14. PubMed ID: 28947123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.
    ;
    Cell; 2019 Aug; 178(4):887-900.e14. PubMed ID: 31398342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
    Podvin S; Reardon HT; Yin K; Mosier C; Hook V
    J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
    Martí E
    Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's Disease: New Frontiers in Therapeutics.
    Pan L; Feigin A
    Curr Neurol Neurosci Rep; 2021 Feb; 21(3):10. PubMed ID: 33586075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.